Holen Sie sich die Stockscreener-App
18.61
1.12%
-0.21
Handel nachbörslich:
18.98
0.37
+1.99%
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Trend Recap: Is UroGen Pharma Ltd a cyclical or defensive stock2026 Reactions & Weekly High Conviction Trade Ideas - baoquankhu1.vn
URGN SEC FilingsUrogen Pharma 10-K, 10-Q, 8-K Forms - stocktitan.net
Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady - Yahoo Finance
UroGen Pharma CMO Schoenberg sells $145k in shares - Investing.com
UroGen Pharma Ltd.Ordinary Shares (NQ: URGN - The Chronicle-Journal
UroGen Pharma Ltd (UR8.DU) Income Statement - Yahoo! Finance Canada
Behavioral Patterns of URGN and Institutional Flows - Stock Traders Daily
Activity Recap: Will UroGen Pharma Ltd stock benefit from M AMarket Volume Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
URGN: D. Boral Capital Maintains Buy Rating with $33 Price Targe - GuruFocus
Urogen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral Capital - marketbeat.com
Hennion & Walsh Asset Management Inc. Boosts Stock Position in Urogen Pharma $URGN - marketbeat.com
UroGen’s Zusduri shows 72% event-free rate at 24 months By Investing.com - Investing.com South Africa
UroGen Pharma (URGN) Announces Positive Phase 3 Trial Results fo - GuruFocus
UroGen’s Zusduri shows 72% event-free rate at 24 months - Investing.com
Urogen Pharma Ltd. Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - marketscreener.com
Bladder cancer drug kept 72.2% of responders event-free for 2 years - stocktitan.net
URGN PE Ratio & Valuation, Is URGN Overvalued - Intellectia AI
Urogen Pharma $URGN Shares Acquired by JPMorgan Chase & Co. - marketbeat.com
Is UroGen Pharma Ltd a cyclical or defensive stockTrade Volume Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
SG Americas Securities LLC Purchases 220,264 Shares of Urogen Pharma $URGN - marketbeat.com
Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by Analysts - marketbeat.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com
Veteran cancer researcher Mark joins Urogen Pharma to drive progress in urologic oncology - Traders Union
Forecast Cut: Can UroGen Pharma Ltd keep up with sector leaders2026 Retail Activity & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
UroGen Pharma Hits Day High with Strong 7.12% Intraday Surge - Markets Mojo
How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities - Yahoo Finance
Live UroGen Pharma Ltd. (URGN) Technical Analysis - Traders Union
UroGen Pharma Ltd. (URGN) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
UroGen Pharma Ltd. (URGN) Stock Price Prediction for 2026, 2030-2040 - Traders Union
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Clinical Setbacks and Cash Burn Con - AD HOC NEWS
URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Biotech Sector Volatility - AD HOC NEWS
UroGen Pharma (URGN) Highlights Key Findings in Bladder Cancer R - GuruFocus
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence - The Manila Times
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report - GlobeNewswire
Bladder Cancer Patients Report Delayed Diagnosis and Gaps in Support - GlobeNewswire Inc.
Jobs Data: Is UroGen Pharma Ltd stock showing strong momentumMarket Volume Report & Consistent Profit Trading Strategies - baoquankhu1.vn
URGN (UroGen Pharma) NonCurrent Deferred Revenue : $0.0 Mil (As of Dec. 2025) - GuruFocus
How (URGN) Movements Inform Risk Allocation Models - Stock Traders Daily
URGN Technical Analysis & ETF Price Forecast - Intellectia AI
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
UroGen closes up 43% ahead of FDA decision on bladder cancer candidate - MSN
UroGen Pharma Q3 2025 Earnings Preview - MSN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
UroGen Pharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
UroGen grants 51,200 stock units to new hires backing cancer drugs - Stock Titan
JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN - MarketBeat
Assessing UroGen Pharma (URGN) Valuation After Recent Share Price Volatility - simplywall.st
Q1 EPS Estimates for Urogen Pharma Lifted by HC Wainwright - MarketBeat
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers - Seeking Alpha
UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push - Yahoo Finance
UroGen’s ZUSDURI Data And Reimbursement Progress Shift Risk Reward Profile - simplywall.st
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):